Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X:

“Pancreatic cancer clinical trials in AACR24:

• CT022 – Mutant KRAS peptide-based vaccine in patients at high risk of developing pancreatic cancer. mKRAS-specific T cell response induced.
• CT134 – Neoadjuvant/adjuvant GM-CSF-secreting allogeneic pancreatic tumor cell vaccine (GVAX) combined with cyclophosphamide, pembrolizumab, and macrophage-targeting CSF1R inhibitor IMC-CS4. Safe and significantly increased activated CD8+ T cells.
• CT025 – Personalized RNA neoantigen vaccines (autogenous cerumen). Induces polyfunctional CD8+ T effector cells of significant longevity, substantial magnitude, and durable function.
• CT031 -Neoadjuvant modified FOLFIRINOX plus nivolumab in borderline resectable pancreas cancer. Favorable rates of R0 resection, PFS, and OS.
• CT016 -Entinostat plus nivolumab. Immunomodulation of myeloid cell populations
• CT080 / 7 -Devimistat plus chemoradiation in inoperable pancreatic cancer. Safe and well tolerated, trial in progress.
• CT106 / 14 – Paclitaxel-eluting PTM-101 film in borderline resectable or locally advanced pancreatic cancer. Surgically feasible, safe, resulted in no systemic paclitaxel exposure, and caused a tumor size reduction.
• CT107 / 15 – Lymph node targeted mKRAS-specific amphiphile vaccine. Durable immunogenicity.
• Siltuximab plus spartalizumab in advanced pancreatic cancer. Safe but did not elicit responses.
• CT214 / 14 – Paricalcitol plus chemotherapy in metastatic pancreatic cancer. Limited clinical benefit.
• Minnelid in chemotherapy-refractory metastatic pancreatic cancer. Safe but did not elicit responses.
• Narmafotinib plus gemcitabine and nab-paclitaxel as first-line therapy in patients with advanced pancreatic cancer (ACCENT trial). Safe and PR in 47% of patients.”

Source: Erman Akkus/X